

Innovation Brief

Urology and Bowel Framework - Indwelling Catheter with Magnetic Release Valve: Cymactive 2.0R Bladder Management System from Ingenion Medical Ltd.

Summary

Disruptive innovation

This briefing introduces a disruptive innovation newly available via NHS Supply Chain: The Cymactive 2.0R Bladder Management System.

Reviewed by clinical specialists and supported by key stakeholders, this device offers a novel approach designed to the management of non-neurogenic urinary retention in people with male anatomy and is an alternative to either intermittent self-catheterisation or an indwelling urinary catheter.

Introduction

This document is intended to inform clinical stakeholders and procurement teams about innovative products that have undergone a clinical review and are now accessible through NHS Supply Chain.

Products featured in this brief may be classified as:

- Disruptive innovations
 - A disruptive innovation is novel.
 - It should offer improvements compared to the existing provision of care.
 - The proposed format should not exist elsewhere (either within or beyond the health and care sector).

Note: While robust evidence or validated savings may not yet be available, early data and clinical insights support the potential for patient and system-level improvements.

Departments / stakeholders for engagement

- NHS procurement teams
- Urologists and urology nurse specialists

Opportunity

This system presents an opportunity to enhance the care of people with male anatomy and non-neurogenic urinary retention, such as prostate related issues, by:


- Offering an alternative management option to indwelling urinary catheter or intermittent self-catheterisation.
- Increasing quality of life.
- Reducing risks associated with current alternatives such as infection.

Innovation Brief

Product overview

This system enables those with male anatomy and suffering from chronic non-neurogenic urinary retention to manage bladder voiding without external tubes or bags (associated with Foley-type catheters), and without repeated insertions of single-use intermittent catheters (and associated medical waste).

The patient's urethra closes over the end, reducing infection risk. Entirely internal, Cymactive is discreet with only two slender removal threads extending from the penis. The patient controls urination with an external magnet to open an integral valve.



Clinical relevance:

- Reducing risks, side effects or complications with an indwelling urinary catheter or intermittent self-catheterisation.
- Increasing the quality of life and self-management or bladder emptying without external drainage bags, such as leg bags.
- Potential for reduction in catheter-associated urinary tract infection (CAUTI).
- Maintaining bladder health function whilst awaiting surgical intervention.

Pathway changes

Cymactive requires insertion and removal by a qualified medical professional with experience of insertion and removal of urinary catheters. It can remain in situ for 30 days.

Supply details

Cymactive intra-urethral catheter with magnet control. Each National Product Code (NPC) is supplied via our eDirect route, has a unit of issue of a box of 15, and a typical lead time of 14 days.

| NPC | MPC | Description |
|----------|--------------|--|
| FUQ85154 | 630 | Replacement actuator (magnet) for valve control |
| FUS85170 | CYM-2R-12 | Silicone catheter with malecot anchor and magnet control includes actuator medium term (30 days) |
| FUS85171 | 630CYM-2R-12 | Silicone catheter with malecot anchor and magnet control includes actuator medium term (30 days) with replacement actuator for valve control |

Contact Details

Zeeshan Rehman - Category Lead
zeeshan.rehman@supplychain.nhs.uk

Care Pathway Team - first point of contact
cpt.vbhenquiries@supplychain.nhs.uk

Lynn Flather - Engagement Specialist
lynn.flather@supplychain.nhs.uk

Danielle Jackson - Category Lead
danielle.jackson@supplychain.nhs.uk